Search Orphan Drug Designations and Approvals
-
Generic Name: | sparsentan |
---|---|
Date Designated: | 01/05/2015 |
Orphan Designation: | Treatment of Focal Segmental Glomerulosclerosis |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Travere Therapeutics, Inc. 3611 Valley Centre Drive, Suite 300 San Diego, California 92130 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-